Thymosin Alpha-1
What the Research Actually Shows
Human: 8 studies, 15 groups · Animal: 2 · In Vitro: 2
The thymic peptide approved in 35 countries that taught immunology the difference between stimulating the immune system and tuning it — and why the biggest trial of all came back empty
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Thymosin Alpha-1 is a 28-amino-acid peptide that comes from your thymus gland. It has been tested in more than 30 clinical trials with over 11,000 people. Doctors in 35 countries prescribe it under the brand name Zadaxin, mainly for chronic hepatitis B. Its safety record is one of the cleanest of any peptide ever studied — no serious side effects linked to the drug across all those patients. The one major letdown: a large, high-quality trial in 2025 tested it for sepsis and found it did not save more lives than a placebo. It works. It is real medicine. But it is not a miracle cure for everything the immune system does.
Your thymus gland is a small organ behind your breastbone that most people never think about unless something goes wrong. It is the boot camp for T-cells — the immune cells that hunt down infections and cancer. By age 40, most of your thymus has been replaced by fat. Thymosin Alpha-1 is one of the hormones the thymus produces during its active years, and it remains one of the best-studied peptides in the history of immunology.
Allan Goldstein isolated Thymosin Alpha-1 from calf thymus tissue at George Washington University in 1977. Nearly five decades later, the synthetic version — marketed as Zadaxin by SciClone Pharmaceuticals — has accumulated a clinical evidence base that few peptides in the Peptidings library can match: regulatory approval in 35+ countries, more than 30 clinical trials, and safety data from over 11,000 human subjects (PMID 38308608). It is the anchor compound of Cluster F because it represents what successful peptide pharmaceutical development actually looks like.
But the honest story includes a critical recent chapter. In 2025, the TESTS trial — the largest and most rigorous sepsis study of Thymosin Alpha-1 ever conducted — returned a negative result (PMID 39814420). Earlier, smaller meta-analyses had suggested a mortality benefit. The definitive trial did not confirm it. That result does not erase 35 countries of regulatory approval or 11,000 patients of safety data. It does demonstrate that even the most promising immune peptide cannot cure everything — and that definitive trials sometimes disappoint where smaller ones suggested hope.
In This Article
Quick Facts: Thymosin Alpha-1 at a Glance
Type
Endogenous immunomodulatory peptide; synthetic version of a natural thymic hormone
Also Known As
Tα1, Thymalfasin, Zadaxin (trade name), Thymosin Alpha 1
Generic Name
Thymalfasin (INN)
Brand Name
Zadaxin (SciClone Pharmaceuticals / Sciclone-Immunomedics)
Molecular Weight
~3,108 Da (28 amino acids, acetylated N-terminus)
Peptide Sequence
Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN (28 aa, N-terminal acetylation)
Endogenous Origin
Cleaved from prothymosin alpha in thymic epithelial cells; part of the thymic hormone complex that drives T-cell maturation
Primary Molecular Function
Immunomodulator acting through TLR2/TLR9 signaling on dendritic cells; drives T-cell differentiation, NK cell activation, and cytokine balance — acts as an immune thermostat, not a simple stimulant
Half-Life
~2 hours (subcutaneous administration)
Route of Administration
Subcutaneous injection (1.6 mg standard clinical dose); no oral formulation — peptide is degraded in the GI tract
Clinical Programs
Approved for chronic hepatitis B (35+ countries); tested in hepatitis C, sepsis (Phase III), COPD exacerbation, severe acute pancreatitis, COVID-19, cancer adjuvant immunotherapy, primary immunodeficiency (DiGeorge syndrome)
Key Trial Result
TESTS Trial (2025, PMID 39814420): Phase III, multicenter, double-blind, placebo-controlled sepsis trial — 28-day mortality 23.4% (Tα1) vs. 24.1% (placebo). Result: NEGATIVE. The definitive sepsis trial did not confirm earlier meta-analysis findings.
International Approvals
Approved as Zadaxin in 35+ countries: China, Italy, India, South Korea, Philippines, Thailand, Peru, Argentina, and across Latin America, Eastern Europe, Middle East, Asia-Pacific
Community Interest
Immune optimization, post-infection recovery, adjuvant to cancer therapy, long COVID, chronic fatigue, general immune "tuning" — community use extends well beyond approved indications
FDA Status
Orphan drug designation for hepatitis B (2001) and DiGeorge syndrome. NOT broadly FDA-approved. Category 2 since 2023 — no longer available through US compounding pharmacies for non-orphan indications.
WADA Status
Not prohibited. Thymosin Alpha-1 is an immunomodulator distinct from Thymosin Beta-4 (TB-500), which IS prohibited under S2 (Peptide Hormones).
Evidence Tier
1 Approved Drug
Verdict
Strong Foundation
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Thymosin Alpha-1?
Pronunciation: THIGH-moh-sin AL-fah wun
Your thymus gland sits behind your sternum, a small, bilobed organ that serves as the training academy for the adaptive immune system. Every T-cell that patrols your body — hunting viruses, killing cancer cells, coordinating immune responses — graduated from the thymus. And one of the molecules that runs that academy is Thymosin Alpha-1: a 28-amino-acid peptide cleaved from the larger precursor protein prothymosin alpha in thymic epithelial cells.
What makes Thymosin Alpha-1 pharmacologically distinctive is not what it does to the immune system, but how it does it. Most immune-modulating drugs either stimulate or suppress. Thymosin Alpha-1 appears to do both — nudging immune function toward balance rather than simply turning it up or down. It signals through Toll-like receptors 2 and 9 (TLR2/TLR9) on dendritic cells, promoting their maturation and their ability to present antigens to T-cells. It drives differentiation of immature thymocytes into mature CD4+ and CD8+ T-cells. It activates natural killer cells. And it modulates cytokine production — increasing interferon-alpha and interferon-gamma while helping to prevent the kind of runaway inflammatory cascade that characterizes sepsis and cytokine storm. Think of it as an immune thermostat rather than an immune accelerator.
The synthetic version, marketed as Zadaxin (thymalfasin), was developed by SciClone Pharmaceuticals and has been prescribed in 35+ countries since the 1990s. The standard clinical dose is 1.6 mg subcutaneous injection, typically given two to three times per week. At ~3,108 Da, it is a mid-sized peptide — larger than the small signaling peptides in Clusters B and G, but small enough for reliable subcutaneous absorption.
PLAIN ENGLISH
Your thymus is like a military academy for immune cells. Thymosin Alpha-1 is one of the drill instructors — it does not just activate immune cells, it trains them to respond appropriately. That is why researchers call it an immunomodulator rather than an immunostimulant: it adjusts the immune response rather than simply cranking it up.
Origins and Discovery
The story of Thymosin Alpha-1 begins in the 1960s, when immunologists were trying to understand why the thymus gland mattered. Neonatal thymectomy experiments had shown that removing the thymus from newborn mice produced catastrophic immune deficiency — but nobody understood the mechanism. The thymus was clearly doing something critical, and the leading hypothesis was that it produced soluble factors — thymic hormones — that directed immune cell development.
Allan Goldstein, working at the University of Texas Medical Branch and later at George Washington University, isolated a crude mixture of thymic peptides from calf thymus tissue in the early 1970s. He called the mixture "Thymosin Fraction 5." From that complex cocktail, his team purified Thymosin Alpha-1 in 1977 — a 28-amino-acid peptide with an acetylated N-terminus that proved to be one of the most potent immunomodulatory components of the fraction.
The synthetic version followed quickly. Unlike many peptides that proved difficult to produce at pharmaceutical scale, Tα1's 28-amino-acid sequence was amenable to solid-phase synthesis. SciClone Pharmaceuticals licensed the compound and pursued clinical development primarily in hepatitis B — an enormous market in Asia, where chronic HBV infection affected hundreds of millions of people. Zadaxin received its first regulatory approval in the mid-1990s, and by the early 2000s it was approved in 35+ countries, primarily across Asia, Latin America, Eastern Europe, and the Middle East.
The United States, however, proved a different story. Despite orphan drug designations for hepatitis B (2001) and DiGeorge syndrome, Tα1 never achieved broad FDA approval. The reasons are complex: the US market was less driven by hepatitis B, the regulatory bar was high, and SciClone's clinical development strategy focused on international markets where the unmet need was greatest. In 2023, the FDA placed Thymosin Alpha-1 in Category 2, removing it from US compounding pharmacy access for non-orphan indications.
PLAIN ENGLISH
Scientists discovered Thymosin Alpha-1 by asking a simple question: what does the thymus gland actually produce? The answer turned out to be a peptide that trains immune cells — and it became a real medicine prescribed in 35 countries. It just never cleared the FDA's bar in the United States, which means American patients face an access barrier that most of the world does not.
Mechanism of Action
Thymosin Alpha-1 operates through at least five interconnected immunomodulatory pathways:
TLR2/TLR9 Signaling and Dendritic Cell Maturation
The primary mechanism involves signaling through Toll-like receptors 2 and 9 on dendritic cells — the antigen-presenting cells that serve as the bridge between innate and adaptive immunity. When Tα1 engages TLR2 and TLR9, it triggers dendritic cell maturation: the cells upregulate MHC class II molecules, co-stimulatory molecules (CD80, CD86), and pro-inflammatory cytokines. Mature dendritic cells are dramatically more effective at activating T-cells than immature ones. This is the rate-limiting step in adaptive immune responses — and Tα1 accelerates it.
PLAIN ENGLISH
Dendritic cells are the intelligence officers of the immune system — they capture foreign invaders, break them down, and present the evidence to T-cells. Thymosin Alpha-1 makes these intelligence officers better at their job, which means T-cells get activated faster and more effectively when an infection arrives.
T-Cell Differentiation and Maturation
Tα1 promotes the differentiation of immature thymocytes (thymic progenitor cells) into mature CD4+ helper T-cells and CD8+ cytotoxic T-cells. This is particularly relevant in immunocompromised patients — cancer patients on chemotherapy, elderly patients with thymic involution, and patients with primary immunodeficiencies like DiGeorge syndrome — where the pool of functional T-cells is depleted. Tα1 does not create T-cells from nothing; it accelerates the maturation of T-cells that are already in the pipeline but have not yet completed their developmental program.
Natural Killer Cell Activation
NK cells are the innate immune system's rapid-response force — they kill virus-infected cells and tumor cells without needing prior antigen exposure. Tα1 enhances NK cell cytotoxicity, increasing their ability to recognize and destroy compromised cells. This NK activation is mechanistically distinct from the dendritic cell pathway and represents a second arm of Tα1's immune-boosting activity.
Cytokine Modulation — The Thermostat Effect
This is where Tα1 becomes genuinely interesting from a pharmacological perspective. It increases production of IL-2 (which drives T-cell proliferation), IFN-α, and IFN-γ (which enhance antiviral defenses). Simultaneously, it modulates excessive pro-inflammatory cytokine release — the kind of dysregulated inflammatory response that drives sepsis and cytokine storm. This bidirectional activity — enhancing specific immune pathways while dampening excessive inflammation — is the "thermostat" effect that distinguishes Tα1 from simple immunostimulants. An immunostimulant turns the dial up. Tα1 adjusts the dial to where it should be.
PLAIN ENGLISH
Most immune-boosting compounds work like a volume knob turned to maximum. Thymosin Alpha-1 works more like a thermostat — it turns up the heat when the system is running cold (immunosuppression) and turns it down when it is running hot (excessive inflammation). That dual action is why researchers have tested it in conditions as different as immune deficiency and sepsis.
Regulatory T-Cell Balance
Emerging evidence suggests Tα1 promotes regulatory T-cell (Treg) differentiation in certain contexts. Tregs are the immune system's peacekeepers — they prevent autoimmune attacks and maintain tolerance. If confirmed, this Treg activity provides a mechanistic explanation for Tα1's apparent ability to modulate rather than simply stimulate: it is simultaneously promoting effector T-cell maturation (attack capability) and Treg differentiation (restraint capability).
Key Research Areas and Studies
Hepatitis B — The Anchor Indication
Chronic hepatitis B affects an estimated 296 million people worldwide and was the primary market driver for Zadaxin's development. Multiple randomized controlled trials demonstrated that Tα1, either as monotherapy or in combination with interferon-alpha, improved rates of viral clearance (HBeAg seroconversion) compared to interferon alone or placebo. The combination of Tα1 + interferon-alpha showed synergistic antiviral effects, with the peptide enhancing the interferon response rather than replacing it. This is the clinical foundation upon which 35+ countries granted regulatory approval.
Hepatitis C
Several RCTs tested Tα1 as part of triple therapy (Tα1 + interferon + ribavirin) for chronic hepatitis C. Results showed modest improvements in sustained virological response in some patient populations. However, the clinical relevance of these findings diminished significantly with the advent of direct-acting antiviral agents (DAAs), which transformed hepatitis C from a chronic disease to a curable infection. Tα1's HCV story illustrates a common pharmaceutical reality: a compound can be pharmacologically active and still become clinically obsolete when better treatments emerge.
Sepsis — The Definitive Disappointment
The sepsis indication was perhaps the most exciting therapeutic hypothesis for Tα1. Sepsis represents a dysregulated immune response to infection — exactly the kind of condition where an immune thermostat should shine. Earlier meta-analyses of smaller RCTs (PMID 27633969, PMID 25532482) had suggested that Tα1 reduced 28-day mortality in sepsis patients.
Then came the TESTS trial (PMID 39814420, 2025) — a Phase III, multicenter, double-blind, randomized, placebo-controlled study. The result was definitive and disappointing: 28-day all-cause mortality was 23.4% in the Tα1 group versus 24.1% in the placebo group. No statistically significant benefit. The largest, most rigorous trial contradicted the signal from smaller studies.
A 2025 systematic review and meta-analysis (PMID 40969554) provides updated pooled analysis incorporating the TESTS trial, and the overall picture has shifted: the earlier mortality benefit signal is substantially weakened when the TESTS trial is included.
PLAIN ENGLISH
The sepsis story is a textbook example of why large, well-designed trials matter. Smaller studies had hinted that Thymosin Alpha-1 could save lives in sepsis. The definitive study — testing hundreds of patients with the gold-standard double-blind design — found no benefit. This does not mean the earlier studies were fraudulent; it means small studies can produce misleading results, and only a large trial can settle the question. The question has been settled.
COPD Acute Exacerbation
A systematic review and meta-analysis of 39 RCTs involving 3,329 patients (PMID 39648386) demonstrated significant improvements in pulmonary function markers, oxygenation parameters, and shortened hospital stays when Tα1 was added to standard therapy for acute COPD exacerbation. This is one of the strongest evidence bases for Tα1 outside of hepatitis B — but with an important caveat: the literature is predominantly from Chinese hospitals and journals, and Western replication remains limited.
Severe Acute Pancreatitis
A 2025 systematic review (PMID 40599771) of 5 RCTs (706 patients) found reduced infection rates and inflammatory markers when Tα1 was added to standard care for severe acute pancreatitis.
COVID-19
The COVID-19 pandemic generated intense interest in Tα1 as an immune modulator for severe disease. A 2022 systematic review (PMC: 9754924) found mixed results, and a 2023 meta-analysis (PMID 37845598) focusing on moderate-to-critical COVID-19 suggested possible benefit in specific subgroups. The overall COVID-19 evidence is insufficient to establish Tα1 as a standard treatment.
Cancer Adjuvant Immunotherapy
Multiple trials have tested Tα1 as an adjuvant to chemotherapy in hepatocellular carcinoma, non-small cell lung cancer, and melanoma. The evidence suggests improved immune reconstitution during chemotherapy — Tα1 helps the immune system recover from the immunosuppressive effects of chemotherapy more quickly. It is not a standalone anticancer agent; it is an immune support during aggressive treatment.
DiGeorge Syndrome and Primary Immunodeficiency
Tα1 holds orphan drug designation in the US for DiGeorge syndrome, a genetic condition characterized by thymic aplasia or hypoplasia leading to severe T-cell deficiency. Case series and open-label data demonstrate meaningful immune reconstitution — exactly what the mechanism predicts. This is perhaps the most mechanistically clean application: the thymus is absent or defective, so you provide the hormone it should have been producing.
PLAIN ENGLISH
Thymosin Alpha-1 has been tested against a remarkable range of diseases — from hepatitis to sepsis to cancer to COVID-19. The pattern is consistent: it helps immune-compromised systems work better, but it is not a dramatic standalone therapy for any single condition. Think of it as an immune tune-up rather than an immune overhaul.
The Geographic Evidence Question
A significant portion of the clinical trial data for Thymosin Alpha-1 — particularly for COPD, pancreatitis, and cancer adjuvant use — originates from Chinese hospitals and journals. This is not incidental: SciClone Pharmaceuticals (later acquired by Sorrento Therapeutics) built its primary commercial market in China, where Zadaxin was a blockbuster drug for hepatitis B and generated hundreds of millions in annual revenue. Clinical trials tend to concentrate where the drug is widely used and where investigators have experience with the compound.
This geographic concentration does not invalidate the data, but it creates two legitimate concerns:
First, replication. The gold standard in biomedical evidence is independent replication across different research groups, institutions, and populations. When most evidence for a given indication comes from one country's hospital system, the evidence is internally consistent but externally unreplicated.
Second, publication practices. Chinese medical journals have been subject to documented concerns about peer review integrity, data fabrication, and citation manipulation. These concerns are systemic and well-documented — they do not mean any specific Tα1 study is fraudulent, but they do mean the overall evidence base carries a methodological asterisk that would not apply to a comparable body of work from, say, European multicenter trials.
PLAIN ENGLISH
Most of the evidence for Thymosin Alpha-1 in conditions like COPD and pancreatitis comes from China, where the drug was most widely prescribed. That does not make the studies wrong, but it does mean they have not been independently confirmed by Western hospitals. When all the supporting evidence comes from one place, we should be honest about that limitation.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"Cures chronic hepatitis B"” | Multiple RCTs demonstrate improved HBeAg seroconversion, especially in combination with interferon-alpha. Approved indication in 35+ countries. Does not "cure" HBV — improves viral clearance rates. | Supported |
| “"Reduces sepsis mortality"” | The definitive TESTS trial (2025, Phase III, placebo-controlled) found NO mortality benefit: 23.4% vs. 24.1% (PMID 39814420). Earlier meta-analyses suggested benefit, but the gold-standard trial was negative. | Unsupported |
| “"Boosts the immune system"” | Demonstrated in multiple clinical settings: enhanced T-cell maturation, NK cell activation, dendritic cell function. "Boost" is imprecise — Tα1 modulates rather than simply stimulates. | Supported |
| “"Helps fight cancer"” | Evidence supports immune reconstitution during chemotherapy. Not a standalone anticancer agent. Adjuvant benefit in HCC and NSCLC trials, primarily from Chinese literature. | Mixed Evidence |
| “"Treats COVID-19"” | Mixed results across meta-analyses. Possible subgroup benefit in moderate-to-critical disease. Not established as a standard COVID-19 treatment. | Mixed Evidence |
| “"Improves COPD exacerbation outcomes"” | Meta-analysis of 39 RCTs (3,329 patients) shows significant improvement in pulmonary function and hospital stay. Evidence is predominantly from Chinese hospitals. | Supported |
| “"Has no side effects"” | Safety data from >11,000 subjects shows no serious drug-related adverse events. Mild injection site reactions and occasional fever/fatigue reported. One of the cleanest safety profiles in peptide pharmacology. | Supported |
| “"Works for autoimmune disease"” | Theoretical basis exists (Treg promotion), but clinical evidence for autoimmune indications is minimal. Theoretical concern that immune stimulation could worsen some autoimmune conditions. | Preclinical Only |
| “"Is the same as TB-500 / Thymosin Beta-4"” | Completely different peptide. Different gene, different structure, different mechanism. Tα1 = immunomodulator (28 aa, thymic). Tβ4 = tissue repair peptide (43 aa, ubiquitous). They share only the word "thymosin" in their name. | Unsupported |
| “"Prevents aging by restoring thymic function"” | Thymic involution is real and Tα1 addresses its downstream effects (T-cell depletion). But Tα1 does not reverse thymic atrophy itself — it provides the hormonal output the atrophied thymus can no longer produce. No RCT has tested anti-aging claims. | Theoretical |
| “"Is available through US compounding pharmacies"” | Category 2 since 2023 — NOT available through US compounding pharmacies for general use. Orphan drug access pathways may still exist for specific indications. Regulatory situation may change. | Unsupported |
| “"Helps with long COVID"” | Mechanistic rationale exists (immune restoration post-viral). No controlled trial data specific to long COVID. Community reports are anecdotal. | Theoretical |
We currently don’t have any vetted partners for this compound. Check back soon.
The Human Evidence Landscape
Thymosin Alpha-1 has one of the most extensive human evidence portfolios in the Peptidings library. A 2024 comprehensive narrative review (PMID 38308608) assessed safety and efficacy data across more than 11,000 human subjects in over 30 clinical trials. This is not a compound where human evidence is thin — it is a compound where human evidence is deep but geographically concentrated and indication-specific.
The Hepatitis B Trials — Regulatory Foundation
Multiple RCTs established the efficacy of Tα1 for chronic hepatitis B, both as monotherapy and in combination with interferon-alpha. These trials formed the regulatory basis for approval in 35+ countries. The evidence quality ranges from adequate to good, with clear demonstration of improved HBeAg seroconversion rates. This is the strongest clinical evidence base.
The TESTS Trial — Sepsis (Phase III, 2025)
The TESTS trial (PMID 39814420) was a Phase III, multicenter, double-blind, randomized, placebo-controlled trial testing Tα1 for sepsis. The primary endpoint — 28-day all-cause mortality — showed no significant difference between Tα1 (23.4%) and placebo (24.1%). This is the single most important recent study for Tα1, because it overturns the positive signal from earlier, smaller meta-analyses. The TESTS trial was well-designed, adequately powered, and its negative result is definitive for the primary sepsis indication.
The COPD Meta-Analysis — Strongest Post-Hepatitis Evidence
A systematic review and meta-analysis of 39 RCTs involving 3,329 patients (PMID 39648386) found significant improvements in pulmonary function, oxygenation, and hospital stay duration for acute COPD exacerbation treated with Tα1 as adjuvant therapy. This represents the largest pooled evidence base for any non-hepatitis indication. The geographic concentration (predominantly Chinese literature) is a limitation but does not negate 39 randomized trials.
The Pancreatitis Signal
Five RCTs (706 patients) in severe acute pancreatitis demonstrated reduced infection rates and inflammatory markers (PMID 40599771). This evidence base is smaller but consistent with Tα1's immunomodulatory mechanism in acute inflammatory states.
The COVID-19 Chapter
The pandemic generated rapid but inconclusive evidence. Meta-analyses (PMC: 9754924, PMID 37845598) produced mixed results. The overall signal suggests possible benefit in severe disease subgroups but falls short of establishing a standard treatment recommendation.
PLAIN ENGLISH
Thymosin Alpha-1 has been studied in more humans than almost any other peptide. The total picture: it genuinely works for hepatitis B (35 countries agree), probably helps in COPD flares (39 trials), and has a clean safety record. But the biggest bet — that it could save lives in sepsis — did not pay off when tested rigorously. The evidence is deep but uneven.
Safety, Risks, and Limitations
Overall Safety Profile
The safety record of Thymosin Alpha-1 across >11,000 human subjects is remarkably clean. The 2024 comprehensive review (PMID 38308608) found no serious adverse events attributable to the drug. Reported side effects include:
- Injection site reactions: mild erythema, swelling, or discomfort at the subcutaneous injection site (the most common adverse event, typically self-limiting)
- Systemic: mild fever, fatigue, and myalgia (occasional, transient, generally in the first few doses)
- No immunosuppression rebound after discontinuation — Tα1 does not appear to create dependency
The Autoimmune Consideration
Tα1 is an immune modulator, and any compound that enhances immune function carries at least a theoretical risk of exacerbating autoimmune conditions. The evidence on this is limited: Tα1 has been studied primarily in immunocompromised populations (hepatitis patients, cancer patients, sepsis patients), not in patients with active autoimmune disease. The Treg-promoting activity suggests bidirectional modulation, but clinical data in lupus, rheumatoid arthritis, or multiple sclerosis is essentially absent.
CRITICAL DISCLAIMER
If you have an active autoimmune condition, the effect of Thymosin Alpha-1 on your disease is unknown. The immune-enhancing effects that make Tα1 beneficial in immunocompromised patients could theoretically worsen autoimmune disease. No clinical trial has tested this directly. Proceed with extreme caution and physician guidance.
Drug Interactions
Tα1 has been studied in combination with interferon-alpha (hepatitis B/C), chemotherapy agents (cancer adjuvant trials), ribavirin, and standard supportive care (sepsis). No significant drug-drug interactions have been identified. The combination with interferon-alpha appears synergistic rather than additive, which is a positive safety signal.
The US Access Problem
The 2023 Category 2 classification effectively removed Tα1 from US compounding pharmacy access. This creates a practical problem: US patients who used Tα1 through compounding pharmacies lost access, and the only legal route is through orphan drug pathways for specific indications or international sources. The regulatory situation may change — several Category 2 peptides are being reconsidered — but as of April 2026, US access remains restricted.
PLAIN ENGLISH
Thymosin Alpha-1 has one of the safest track records of any peptide ever tested — no serious side effects across more than 11,000 patients. The main limitation is not safety but access: the FDA has restricted US compounding, even though 35 other countries prescribe it freely. If you have an autoimmune condition, the safety picture is less clear because the drug has not been tested in that population.
Legal and Regulatory Status
FDA Status: Orphan drug designation for chronic hepatitis B (2001) and DiGeorge syndrome. Not broadly FDA-approved for any general indication. Category 2 classification since 2023 prohibits compounding by 503A and 503B pharmacies for non-orphan indications. The February 2026 HHS announcement indicated potential reclassification of some Category 2 peptides to Category 1 — Thymosin Alpha-1's final status under this review is pending.
International Approvals: Approved as Zadaxin in 35+ countries including China (where it was a blockbuster), Italy, India, South Korea, Philippines, Thailand, Peru, Argentina, and across Latin America, Eastern Europe, Middle East, and Asia-Pacific regions.
WADA Status: Not prohibited. Thymosin Alpha-1 is an immunomodulatory peptide classified distinctly from Thymosin Beta-4 (TB-500), which IS prohibited under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Athletes should note the distinction — the two "thymosin" peptides are pharmacologically unrelated. WADA has not flagged Tα1 under any prohibited category. Athletes should verify current status through WADA's annual list.
Compounding Access (US): Category 2 — not available through US compounding pharmacies for general use. This is a regulatory access barrier, not a safety judgment. The FDA's Category 2 list includes compounds that do not meet the agency's evaluation criteria for compounding, which is a different standard than "unsafe" or "ineffective."
Research Protocols and Formulation Considerations
Standard Clinical Dosing Protocol
The approved Zadaxin protocol is 1.6 mg administered subcutaneously two to three times per week. This dose was established through dose-finding studies and represents the standard across most clinical trials and approved indications.
Reconstitution and Storage
- Form: Supplied as lyophilized powder (Zadaxin) or as reconstituted solution
- Reconstitution: Bacteriostatic water for injection (when using lyophilized form)
- Storage: 2–8°C (36–46°F) for reconstituted solution; lyophilized powder is more stable at room temperature
- Stability: Reconstituted solution should be used within 14 days when stored at 2–8°C (36–46°F)
Injection Technique
Subcutaneous injection in the abdomen or upper arm. Standard subcutaneous injection technique — see Peptidings [Injection Technique Guide](/guides/injection-technique/) for detailed instructions.
Dosing in Published Research
The following table summarizes dosing protocols for Thymosin Alpha-1 as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.
Approved Dosing (Zadaxin)
| Indication | Dose | Frequency | Duration | Source |
|---|---|---|---|---|
| Chronic Hepatitis B (monotherapy) | 1.6 mg SC | Twice weekly | 6–12 months | Zadaxin prescribing information (international) |
| Chronic Hepatitis B (+ interferon-α) | 1.6 mg SC | Twice weekly | 6 months concurrent with IFN-α | Multiple RCTs |
| Sepsis (TESTS trial) | 1.6 mg SC | Twice daily × 5 days, then daily × 2 days | 7-day course | PMID 39814420 |
| COPD exacerbation (adjuvant) | 1.6 mg SC | Daily or twice weekly | During acute exacerbation | Meta-analysis (PMID 39648386) |
PLAIN ENGLISH
The standard dose is the same across almost every study: 1.6 mg injected under the skin, two or three times a week. The sepsis trial used a more aggressive schedule — twice daily for five days — because sepsis is an acute emergency, not a chronic condition.
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Community Protocols — Observation, Not Endorsement
| Route | Common Protocol | Evidence Basis | Dose Range | Key Risks |
|---|---|---|---|---|
| Subcutaneous | 1.6 mg 2–3×/week (mirrors Zadaxin) | Clinical trial dosing — this is the one community protocol with actual published support | 1.0–3.0 mg per injection | Low — mirrors approved protocols |
| Subcutaneous (high-dose) | 3.0–6.0 mg daily | No published basis; community self-experimentation | 3.0–6.0 mg daily | Unknown — exceeds any published protocol |
| Subcutaneous (immune "loading") | 3.0 mg daily × 14 days | Community cancer adjuvant protocol; no trial support for this schedule | 3.0 mg daily | Unknown safety at sustained high doses |
The community dosing landscape for Tα1 is unusual in that many community users simply follow the published clinical protocol (1.6 mg SC, 2–3×/week). This is one of the few peptides where community practice and clinical evidence actually align at the base level. Higher-dose protocols exceeding 3.0 mg daily have no published support and represent genuine self-experimentation.
CRITICAL DISCLAIMER
Community protocols at 3.0 mg or higher daily exceed all published dosing. The clean safety record of Tα1 is based on the 1.6 mg dose. Higher doses have not been systematically evaluated for adverse effects.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Thymosin Alpha-1 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Thymosin Alpha-1 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
| Compound | Type | Evidence Tier | Verdict | Mechanism | Primary Use Case | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| Thymosin Alpha-1 | 28-amino-acid peptide (thymus gland derivative) | Tier 1 — Approved Drug | Strong Foundation | Dendritic cell maturation + T-cell differentiation (Th1/Th17/Treg balance) + NK cell activation + TLR signaling enhancement; bidirectional immune modulation | Immune modulation; hepatitis B/C adjunct; vaccine enhancement; cancer immunotherapy adjunct | >11,000 in 30+ trials (Phase III TESTS sepsis N=3,600; HBV meta-analyses; adjuvant cancer trials) | Approved as Zadaxin in 35+ countries (NOT US/EU); US Category 2 compounding | Not specifically named; thymic peptides not prohibited | US access barrier (Category 2 compounding only); TESTS Phase III sepsis trial negative; evidence concentrated in Chinese/Italian institutions; geographic publication bias |
| LL-37 | 37-amino-acid peptide (human cathelicidin — only human member) | Tier 3 — Pilot / Limited Human Data | Eyes Open | Direct membrane disruption of pathogens + chemokine-like immune cell recruitment + TLR modulation + angiogenesis + wound healing via keratinocyte/fibroblast migration; vitamin D–regulated expression via CAMP gene | Innate immune defense; wound healing; antimicrobial; anti-biofilm | ~74 across 2 small RCTs (venous leg ulcers N=34; diabetic foot ulcers N≈40) — all topical wound healing | Not approved | Not specifically prohibited | Cancer paradox (pro-tumorigenic at ~5 μg/mL in multiple cancers); route problem (injection destroys membrane-disruption advantage); two tiny topical RCTs only; no systemic human dosing data |
| KPV | Tripeptide (Lys-Pro-Val — C-terminal fragment of α-MSH) | Tier 4 — Preclinical Only | Thin Ice | NF-κB suppression at nanomolar concentrations + MAPK/ERK inhibition + PepT1-mediated intestinal uptake (transporter upregulated during IBD); does NOT bind melanocortin receptors | Anti-inflammatory; IBD/gut inflammation; immune modulation | None — zero human studies | Not approved | Not specifically prohibited | Zero human data; single research group dominance; nanoparticle formulation used in best studies not commercially available; raw peptide ≠ study formulation; route paradox (injection bypasses PepT1 gut transport) |
Related Compounds: How Thymosin Alpha-1 Compares
Thymosin Alpha-1 belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Immune Health cluster.
Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.
| Compound | Type | Evidence Tier | Verdict | Mechanism | Primary Use Case | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| Thymosin Alpha-1 | 28-amino-acid peptide (thymus gland derivative) | Tier 1 — Approved Drug | Strong Foundation | Dendritic cell maturation + T-cell differentiation (Th1/Th17/Treg balance) + NK cell activation + TLR signaling enhancement; bidirectional immune modulation | Immune modulation; hepatitis B/C adjunct; vaccine enhancement; cancer immunotherapy adjunct | >11,000 in 30+ trials (Phase III TESTS sepsis N=3,600; HBV meta-analyses; adjuvant cancer trials) | Approved as Zadaxin in 35+ countries (NOT US/EU); US Category 2 compounding | Not specifically named; thymic peptides not prohibited | US access barrier (Category 2 compounding only); TESTS Phase III sepsis trial negative; evidence concentrated in Chinese/Italian institutions; geographic publication bias |
| LL-37 | 37-amino-acid peptide (human cathelicidin — only human member) | Tier 3 — Pilot / Limited Human Data | Eyes Open | Direct membrane disruption of pathogens + chemokine-like immune cell recruitment + TLR modulation + angiogenesis + wound healing via keratinocyte/fibroblast migration; vitamin D–regulated expression via CAMP gene | Innate immune defense; wound healing; antimicrobial; anti-biofilm | ~74 across 2 small RCTs (venous leg ulcers N=34; diabetic foot ulcers N≈40) — all topical wound healing | Not approved | Not specifically prohibited | Cancer paradox (pro-tumorigenic at ~5 μg/mL in multiple cancers); route problem (injection destroys membrane-disruption advantage); two tiny topical RCTs only; no systemic human dosing data |
| KPV | Tripeptide (Lys-Pro-Val — C-terminal fragment of α-MSH) | Tier 4 — Preclinical Only | Thin Ice | NF-κB suppression at nanomolar concentrations + MAPK/ERK inhibition + PepT1-mediated intestinal uptake (transporter upregulated during IBD); does NOT bind melanocortin receptors | Anti-inflammatory; IBD/gut inflammation; immune modulation | None — zero human studies | Not approved | Not specifically prohibited | Zero human data; single research group dominance; nanoparticle formulation used in best studies not commercially available; raw peptide ≠ study formulation; route paradox (injection bypasses PepT1 gut transport) |
Frequently Asked Questions
What is Thymosin Alpha-1?
Thymosin Alpha-1 is a 28-amino-acid peptide originally produced by the thymus gland. The synthetic version, sold as Zadaxin, is approved in 35+ countries as an immunomodulatory drug, primarily for chronic hepatitis B. It works by tuning the immune system — enhancing T-cell maturation, natural killer cell activity, and dendritic cell function — rather than simply stimulating it.
Is Thymosin Alpha-1 FDA-approved?
Not broadly. It has orphan drug designations for hepatitis B and DiGeorge syndrome in the US, but no general FDA approval. It was placed in Category 2 in 2023, removing it from US compounding pharmacy access. However, it is approved as Zadaxin in 35+ other countries.
Is Thymosin Alpha-1 the same as TB-500 or Thymosin Beta-4?
No. They are completely different peptides from different genes with different mechanisms. Thymosin Alpha-1 is a 28-amino-acid immunomodulatory peptide from the thymus. Thymosin Beta-4 is a 43-amino-acid tissue repair peptide found in virtually all cells. They share the word "thymosin" because both were originally isolated from thymic tissue, but they are pharmacologically unrelated.
What is the standard dose of Thymosin Alpha-1?
The standard clinical dose is 1.6 mg administered subcutaneously, two to three times per week. This is the dose used in most clinical trials and in the approved Zadaxin product. It has been studied at this dose in over 11,000 patients.
Did Thymosin Alpha-1 fail for sepsis?
The definitive TESTS trial (2025) did find that Tα1 did not reduce 28-day mortality compared to placebo in sepsis patients. Earlier, smaller studies had suggested benefit, but the gold-standard trial was negative. This does not invalidate Tα1's efficacy for other indications — it means the sepsis hypothesis was not confirmed.
Is Thymosin Alpha-1 safe?
The safety profile across >11,000 human subjects is one of the cleanest in peptide pharmacology. No serious drug-related adverse events have been identified. Common side effects are mild: injection site reactions, occasional low-grade fever, and transient fatigue. The main unknown is effects in patients with active autoimmune disease.
Can Thymosin Alpha-1 help with cancer?
It has been studied as an adjuvant to chemotherapy — meaning it is used alongside cancer drugs, not instead of them. Evidence suggests it helps the immune system recover from chemotherapy-induced immunosuppression. It is not a standalone cancer treatment and should never be used as a substitute for oncologist-directed care.
Does Thymosin Alpha-1 work for COVID-19?
The evidence is mixed. Meta-analyses suggest possible benefit in severe disease subgroups, but the overall data does not establish Tα1 as a standard COVID-19 treatment. It was one of many immune-modulating compounds tested during the pandemic with inconclusive results.
Why is most of the evidence from China?
SciClone Pharmaceuticals built its primary market for Zadaxin in China, where chronic hepatitis B affected hundreds of millions of people. Clinical trials followed the market — most Tα1 research was conducted in Chinese hospitals because that is where the drug was most widely prescribed. The evidence is real but geographically concentrated.
Can I get Thymosin Alpha-1 in the United States?
As of April 2026, US access is restricted. Category 2 classification (2023) removed Tα1 from compounding pharmacy access. Orphan drug pathways may exist for specific indications. International sources are available but carry legal and quality considerations. The regulatory landscape may change — several Category 2 peptides are under review.
How does Thymosin Alpha-1 compare to other immune peptides?
Tα1 is the most clinically validated immune peptide in the Peptidings library. LL-37 has antimicrobial activity but only two small topical trials. KPV has anti-inflammatory potential but zero human data. Tα1 has 35 countries of approval and >11,000 subjects studied. For immune health, it is the benchmark.
Is Thymosin Alpha-1 banned by WADA?
No. Thymosin Alpha-1 is not on the WADA Prohibited List. It is distinct from Thymosin Beta-4 (TB-500), which IS prohibited under S2. Athletes should verify current status annually.
---
Summary of Key Findings
Thymosin Alpha-1 is the anchor of Cluster F — Immune Health — and represents what a successful peptide pharmaceutical looks like: real regulatory approval, extensive clinical trials, a well-characterized mechanism, and a safety profile built on data from over 11,000 human subjects.
1. Hepatitis B efficacy is established. Multiple RCTs and regulatory approval in 35+ countries confirm that Tα1 improves viral clearance in chronic HBV, particularly in combination with interferon-alpha.
2. The sepsis hypothesis did not survive definitive testing. The 2025 TESTS trial — Phase III, placebo-controlled, the largest sepsis trial of Tα1 ever conducted — found no mortality benefit. This overturns earlier meta-analyses of smaller studies.
3. COPD exacerbation evidence is substantial but geographically concentrated. A meta-analysis of 39 RCTs (3,329 patients) shows meaningful clinical benefit, but the evidence comes predominantly from Chinese hospitals.
4. The mechanism is genuinely bidirectional. Tα1 enhances immune function (T-cell maturation, NK activation, dendritic cell function) while modulating excessive inflammation. This "thermostat" effect distinguishes it from simple immunostimulants.
5. Safety is exceptional. No serious drug-related adverse events across >11,000 subjects. The one significant gap: no data in patients with active autoimmune disease.
6. US access is restricted. Category 2 since 2023. This is a regulatory barrier, not a safety judgment. The rest of the world prescribes it freely.
7. Community protocols largely mirror clinical evidence. Unusually for the peptide space, most community users follow the published 1.6 mg SC dose — though some high-dose protocols exceed all published evidence.
PLAIN ENGLISH
Thymosin Alpha-1 is real medicine with real evidence. It is approved in 35 countries. It has been tested in over 11,000 people with no serious side effects. The strongest evidence is for hepatitis B. The biggest disappointment was sepsis — the definitive trial came back negative. For immune health, it is the most evidence-backed peptide on this site, and that matters even though it is not perfect.
Verdict Recapitulation
Thymosin Alpha-1 earns its Tier 1 designation and Strong Foundation verdict not because every trial succeeded — the TESTS sepsis trial is a prominent failure — but because the overall portfolio represents the deepest and most rigorous clinical evidence base of any immune peptide in the Peptidings library. The compound that Allan Goldstein isolated from calf thymus nearly fifty years ago has become a real pharmaceutical prescribed to real patients in real hospitals across 35 countries. The immune thermostat works. It just does not work for everything.
For readers considering Thymosin Alpha-1, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Thymosin Alpha-1
Further Reading and Resources
If you want to go deeper on Thymosin Alpha-1, the evidence landscape for immune health peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Immune Health Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Thymosin Alpha-1 — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Dominari A, Hathaway D III, Pandav K, et al. (2024). "Thymalfasin: Scoping the evidence on safety and efficacy of thymosin alpha 1." Comprehensive narrative review. PMID 38308608
- TESTS Trial Investigators (2025). "Thymosin alpha 1 in adults with sepsis: TESTS, a multicenter, double-blind, randomized, placebo-controlled trial." Phase III RCT. PMID 39814420
- Li H, et al. (2024). "Thymosin alpha-1 as adjuvant therapy for acute exacerbation of COPD: A systematic review and meta-analysis of 39 RCTs." PMID 39648386
- Zhang Y, et al. (2025). "Thymosin alpha 1 for severe acute pancreatitis: A systematic review and meta-analysis." PMID 40599771
- Li H, et al. (2025). "Updated systematic review and meta-analysis of thymosin alpha-1 in sepsis." PMID 40969554
- Tao N, et al. (2022). "Effect of thymosin alpha-1 on mortality of COVID-19: A systematic review and meta-analysis." PMC: 9754924
- Zhou Y, et al. (2023). "Thymosin alpha-1 for moderate to critical COVID-19: A meta-analysis." PMID 37845598
- Romani L, et al. (2012). "Thymosin alpha-1 activates dendritic cells for anti-fungal Th1 resistance through TLR signaling." PMID 22421987
- Goldstein AL, Goldstein AL (2009). "From lab to bedside: emerging clinical applications of thymosin alpha-1." Expert Opinion on Biological Therapy. PMID 19392576
- Garaci E, et al. (2012). "Thymosin alpha-1: from bench to bedside." Annals of the New York Academy of Sciences. PMID 22612369
- Wu M, et al. (2016). "Meta-analysis of thymosin alpha-1 for sepsis." PMID 27633969
- Liu Y, et al. (2015). "Earlier meta-analysis of thymosin alpha-1 in sepsis." PMID 25532482
- King R, Tuthill C (2016). "Immune modulation with thymosin alpha 1 treatment." Vitamins and Hormones. PMID 26827951
- Naylor PH, Goldstein AL (2020). "Thymosin alpha-1 comprehensive review." PMC: 7747025
DISCLAIMER
Thymosin Alpha-1 is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 08, 2026. Next scheduled review: October 05, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.